Grosicki, S. Simonova, M. Spicka, I. Pour, L. Kriachok, I. Gavriatopoulou, M. Pylypenko, H. Auner, H.W. Leleu, X. Doronin, V. Usenko, G. Bahlis, N.J. Hajek, R. Benjamin, R. Dolai, T.K. Sinha, D.K. Venner, C.P. Garg, M. Gironella, M. Jurczyszyn, A. Robak, P. Galli, M. Wallington-Beddoe, C. Radinoff, A. Salogub, G. Stevens, D.A. Basu, S. Liberati, A.M. Quach, H. Goranova-Marinova, V.S. Bila, J. Katodritou, E. Oliynyk, H. Korenkova, S. Kumar, J. Jagannath, S. Moreau, P. Levy, M. White, D. Gatt, M.E. Facon, T. Mateos, M.V. Cavo, M. Reece, D. Anderson, L.D., Jr Saint-Martin, J.-R. Jeha, J. Joshi, A.A. Chai, Y. Li, L. Peddagali, V. Arazy, M. Shah, J. Shacham, S. Kauffman, M.G. Dimopoulos, M.A. Richardson, P.G. Delimpasi, S., Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial, The Lancet Neurology, (396), 1563-1573, 2020, The Lancet Publishing Group,